April 17th 2025
The PD-L1 IHC 22C3 pharmDx assay has been granted European IVDR certification for identifying pembrolizumab eligibility in gastric/GEJ adenocarcinoma.
April 16th 2025
Nerea Lopetegui-Lia, MD, discusses the prevalence of and risk factors for triple-negative breast cancer, and strategies that may improve survival outcomes.
April 15th 2025
Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.
April 14th 2025
Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.
April 12th 2025
Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.
April 11th 2025
Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.
April 9th 2025
María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.
Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.
April 8th 2025
Clonal neoantigen load was significantly associated with promising responses to PD-1/PD-L1 and CTLA-4 combination therapy in RCC.
April 5th 2025
Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.
April 4th 2025
Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.
April 2nd 2025
Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.
April 1st 2025
Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.
Updated KEYNOTE-799 data continued to show robust activity with pembrolizumab plus concurrent chemoradiation in unresectable stage III NSCLC.
March 29th 2025
The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.
March 28th 2025
The FDA approved perioperative durvalumab plus chemotherapy for muscle-invasive bladder cancer.
The EMA’s CHMP has recommended the approval of perioperative nivolumab plus chemotherapy in resectable PD-L1–positive non–small cell lung cancer.
Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.
Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.
